Literature DB >> 1600348

Cellular origin of aldosteronomas.

A Ganguly1.   

Abstract

In the 1950s, after years of suspicion and work by many investigators regarding a potent mineralocorticoid hormone from the adrenal cortex, aldosterone was at last isolated and chemically identified [40, 41]. Soon after, Jerome Conn was the first to report [11] the clinical correlate of excessive secretion of aldosterone from a benign adrenocortical tumor manifested by hypertension and hypokalemia with the increased urinary excretion of aldosterone. This tumor is often called as aldosteronoma, and the disorder produced by it has been called primary aldosteronism by Conn. In the vast majority of patients harboring such tumors, the hypertension is cured by the resection of the tumor [12, 51], although some suggest that the hypertension may recur in a proportion of apparently cured patients [3, 36]. Thus, primary aldosteronism represents one of a few potentially curable forms of hypertension. Since aldosterone is elaborated normally by the zona glomerulosa cells of the adrenal, it has been assumed that all aldosteronomas originate from the cells of the glomerulosa zone. A clonal origin of aldosteronomas has also been suggested [28]. Some earlier and recent developments, however, indicate that functionally there may be more than one type of aldosteronomas and that their cellular origins might be different.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600348     DOI: 10.1007/bf00235519

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  49 in total

1.  [Constitution of aldosterone, a new mineralocorticoid].

Authors:  S A SIMPSON; J F TAIT; A WETTSTEIN; R NEHER; J VON EUW; O SCHINDLER; T REICHSTEIN
Journal:  Experientia       Date:  1954-03-15

2.  Primary aldosteronism: diagnosis, localization, and treatment.

Authors:  M H Weinberger; C E Grim; J W Hollifield; D C Kem; A Ganguly; N J Kramer; H Y Yune; H Wellman; J P Donohue
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

3.  Activity of [des-aspartyl1]-angiotensin II in primary aldosteronism.

Authors:  R M Carey; C R Ayers; E D Vaughan; M J Peach; S M Herf
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

4.  Functional black adenoma of the adrenal cortex. A rare cause of primary aldosteronism.

Authors:  R H Caplan; R L Virata
Journal:  Am J Clin Pathol       Date:  1974-07       Impact factor: 2.493

5.  Primary aldosteronism: surgical management and pathologic findings.

Authors:  J T Priestley; D O Ferris; W H ReMine; L B Woolner
Journal:  Mayo Clin Proc       Date:  1968-11       Impact factor: 7.616

6.  Primary aldosteronism.

Authors:  J C Melby
Journal:  Kidney Int       Date:  1984-11       Impact factor: 10.612

7.  Clinical, biochemical and pathological features of low-renin ("primary") hyperaldosteronism.

Authors:  J B Ferriss; D G Beevers; J J Brown; D L Davies; R Fraser; A F Lever; P Mason; A M Neville; J I Robertson
Journal:  Am Heart J       Date:  1978-03       Impact factor: 4.749

8.  Primary aldosteronism: effects of inhibition of ACTH and potassium administration on plasma aldosterone concentration.

Authors:  A Ganguly; J A Luetscher; M H Weinberger
Journal:  Clin Exp Hypertens A       Date:  1982

9.  The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism.

Authors:  M Wisgerhof; R D Brown; M J Hogan; P C Carpenter; A J Edis
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

View more
  2 in total

1.  Benign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids.

Authors:  Vivienne Yoon; Aliya Heyliger; Takashi Maekawa; Hironobu Sasano; Kelley Carrick; Stacey Woodruff; Jennifer Rabaglia; Richard J Auchus; Hans K Ghayee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-09-23

2.  Exploration of KCNJ5 Somatic Mutation and CYP11B1/CYP11B2 Staining in Multiple Nodules in Primary Aldosteronism.

Authors:  Jing Xie; Cui Zhang; Xuefeng Wang; Yiran Jiang; Luming Wu; Lei Ye; Xuan Wang; Wen Xie; Haimin Xu; Weiqing Wang
Journal:  Front Med (Lausanne)       Date:  2022-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.